| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 214.992 | 732.938 | 464.043 | 698.291 | 525.448 | 520.817 | 491.348 | 483.830 |
| Total Income - EUR | - | - | 214.992 | 738.512 | 464.981 | 698.365 | 528.375 | 523.181 | 498.136 | 483.864 |
| Total Expenses - EUR | - | - | 115.795 | 589.783 | 427.735 | 608.362 | 458.748 | 309.453 | 421.727 | 463.240 |
| Gross Profit/Loss - EUR | - | - | 99.197 | 148.729 | 37.246 | 90.003 | 69.627 | 213.728 | 76.409 | 20.625 |
| Net Profit/Loss - EUR | - | - | 95.527 | 141.399 | 32.605 | 83.546 | 65.007 | 208.780 | 71.539 | 13.532 |
| Employees | - | - | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Check the financial reports for the company - Naturastudio Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 127 | 125 | 122 | 1.573 | 1.517 | 1.451 | 2.142 |
| Current Assets | - | - | 133.551 | 263.791 | 264.775 | 363.368 | 362.995 | 620.379 | 357.480 | 205.479 |
| Inventories | - | - | 9.644 | 45.627 | 34.489 | 24.837 | 17.721 | 168.200 | 54.811 | 10.910 |
| Receivables | - | - | 77.370 | 85.798 | 55.219 | 57.797 | 52.672 | 63.753 | 226.536 | 160.000 |
| Cash | - | - | 46.536 | 132.366 | 175.067 | 280.734 | 292.601 | 388.426 | 76.132 | 34.569 |
| Shareholders Funds | - | - | 95.545 | 194.361 | 171.283 | 251.582 | 270.580 | 480.199 | 241.395 | 91.294 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 38.041 | 69.557 | 93.616 | 111.908 | 93.988 | 141.697 | 117.643 | 116.602 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Naturastudio Pharma Srl